- Head of R&D Unit　Ken Takeshita
Head of Global Oncology Development　Mark Rutstein
PLAY LIST
- ESMO presentations
- Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase 3 study TROPION-Lung01
- TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer with actionable genomic alterations
- Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previouslytreated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer: Primary results from the randomised Phase 3 TROPION-Breast01 trial
- Datopotamab Deruxtecan (Dato-DXd) + Durvalumab (D) as First-Line (1L) Treatment for Unresectable Locally Advanced/Metastatic Triple-Negative Breast Cancer (a/mTNBC)
- Trastuzumab deruxtecan (T-DXd) for pretreated patients withHER2-expressing solid tumors: primary analysis from the DESTINY-PanTumor02 (DP-02) study
- Raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients with previously treated ovarian cancer (OVC): subgroup analysis of a first-in-human Phase 1 study
- Ifinatamab Deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: Updated clinical and biomarker results from a phase 1/2 study
- Q&A
